Achieve TMS
Achieve TMS is a private healthcare provider founded in 2016 in San Diego that operates clinics delivering FDA-cleared NeuroStar TMS therapy and FDA-approved SPRAVATO esketamine treatments to adults with depression, particularly treatment-resistant depression.
- Company typePrivate
- Founded2016
- HeadquartersSan Diego, United States
- Headcount—
- GTM typeB2C
- OfferingServices
What Achieve TMS does
Achieve TMS is a private healthcare services provider founded in 2016 and headquartered in San Diego that delivers FDA-cleared and FDA-approved depression treatments to adults suffering from major depressive disorder, including treatment-resistant depression. The company operates physical clinic locations where patients receive in-person treatment, and its core offerings are NeuroStar TMS Therapy (transcranial magnetic stimulation, FDA-cleared) and SPRAVATO (esketamine nasal spray, FDA-approved), both supplied through technology and licensing partnerships with Neuronetics and Janssen Pharmaceuticals respectively. The treatments target adults with depression, particularly those who have not achieved relief through traditional antidepressant medications or talk therapy, and patients with MDD accompanied by suicidal ideation.
The company generates revenue by delivering recurring treatment services at clinic locations, with most major insurance plans, Medicare, and Medicaid providing coverage at various sites. Pricing is not publicly disclosed; instead, the company manages the entire insurance workflow on behalf of patients — including coverage verification, claims filing, and appeals — which serves as a patient-friction-reduction mechanism and a core part of the value proposition. Patient acquisition runs through direct-to-consumer channels including a toll-free consultation line, online PHQ-9/PHQ-10 self-assessment quizzes, website content, and patient testimonial stories, with a separate provider-referral pathway for clinicians.
The business model is that of a clinic operator rather than a product manufacturer: Achieve TMS delivers externally-developed FDA-regulated treatments through its own physical footprint and operational infrastructure. Strategic relationships with the technology licensors (Neuronetics, Janssen), insurance carriers, and LegitScript (for healthcare merchant verification) form the operational backbone, and HIPAA compliance is maintained for patient data handling. No funding rounds, M&A activity, leadership details, or headcount data are disclosed in the source material, limiting visibility into the company's scale and capital structure.
Achieve TMS firmographics
Firmographics- Name
- Achieve TMS
- Legal name
- Greenbrook TMS NeuroHealth Centers
- Website
- https://achievetms.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Short description
- Achieve TMS is a private healthcare provider founded in 2016 in San Diego that operates clinics delivering FDA-cleared NeuroStar TMS therapy and FDA-approved SPRAVATO esketamine treatments to adults with depression, particularly treatment-resistant depression.
- Ownership category
- akta.pro rank
Where Achieve TMS is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Markets served
Achieve TMS business model
Business model- GTM type
- B2C
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure
Revenue model
- Patient Treatment Services: Revenue generated from providing TMS therapy and esketamine treatment services to patients at clinic locations. Treatments are typically covered by insurance including Medicare and Medicaid.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Achieve TMS product offering
Product offeringCore offering
Achieve TMS provides in-person depression treatment services at physical clinic locations, delivering FDA-cleared NeuroStar TMS (Transcranial Magnetic Stimulation) therapy and FDA-approved SPRAVATO (esketamine) nasal spray treatments to adults suffering from depression, including treatment-resistant depression and major depressive disorder with suicidal thoughts. Treatments are administered by clinical staff and billed primarily through major insurance carriers, with Medicare and Medicaid coverage available at various locations and the company handling all insurance paperwork, claims, and appeals on the patient's behalf.
Product overview
Greenbrook TMS (Achieve TMS) offers two distinct FDA-approved/cleared depression treatments: NeuroStar TMS Therapy (FDA-cleared transcranial magnetic stimulation) and SPRAVATO® (FDA-approved esketamine nasal spray). NeuroStar TMS is a non-medication, non-invasive treatment that targets specific brain areas, while SPRAVATO® is an FDA-approved esketamine formulation delivered as a nasal spray for treatment-resistant depression. Both treatments can be used as stand-alone therapy or in combination with existing medications.
Differentiator
Problem solved
Functional benefit
Companies that use Achieve TMS
Customer profileNamed customers3 records
Segments1 record
Ideal customer profiles1 record
Achieve TMS technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Achieve TMS partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and minor.
- NeuroStar (Neuronetics)coreGreenbrook provides NeuroStar TMS Therapy, an FDA-cleared non-invasive depression treatment using transcranial magnetic stimulation technology developed by Neuronetics. The company operates as a provider of this technology at their clinic locations.
- Janssen (SPRAVATO)coreGreenbrook offers SPRAVATO (esketamine) nasal spray, an FDA-approved ketamine-based antidepressant treatment for treatment-resistant depression, licensed from Janssen Pharmaceuticals.
- Insurance CompaniescoreThe company works directly with insurance companies to get coverage, file and process claims, and help with appeals when needed. Services covered by major insurance companies including Medicare and Medicaid at various locations.
- LegitScriptminorLegitScript verification partner providing healthcare merchant monitoring and verification services for the company's website.
Recent moves2 records
Expansion highlights4 records
Achieve TMS competitors and assessment
Company assessmentEmerging players
- Cerebral: Cerebral is a digital mental health platform that provides online psychiatry and medication management. It represents the emerging telehealth-and-medication front door that competes for newly diagnosed depression patients before they progress to TRD.
- Talkspace: Talkspace is an online therapy and psychiatry platform. It competes for the same adult depression patient pool via a fully remote, lower-friction model, and is a relevant comparator on patient acquisition economics.
- Brightside Health: Brightside Health combines online psychiatric care with pharmacology and is expanding into interventional depression treatments. It is an emerging competitor in the digital-to-interventional depression care pathway.
Direct peers
- Mindpath Health: Mindpath Health is a multi-state outpatient psychiatry and psychology group that integrates TMS and SPRAVATO into its treatment offerings. It is a direct specialty competitor for depression referrals and treated patients.
- Greenbrook TMS NeuroHealth Centers: Greenbrook operates a multi-state network of outpatient clinics delivering NeuroStar TMS and SPRAVATO under the same dual-modality model that defines Achieve TMS. It is the closest direct competitor by product mix, patient population, and clinical operating model.
Broad incumbents
- LifeStance Health: LifeStance is one of the largest US outpatient mental health platforms, offering psychiatric evaluation, therapy, and increasingly TMS and esketamine services. It competes for the same patient population and referral channels at much greater scale.
- Acadia Healthcare: Acadia operates behavioral health hospitals and outpatient programs across the US, including psychiatric residential and intensive outpatient services. It competes for higher-acuity behavioral health patients and the payer relationships that fund them.
- Neuronetics: Neuronetics manufactures NeuroStar TMS, the device that anchors Achieve TMS's core service. As the upstream technology owner and a publicly traded firm (NASDAQ: NTGN), it is both a critical supplier and a comparable public-market benchmark for TMS economics.
- Brainsway: Brainsway develops and commercializes deep TMS systems for depression and other psychiatric indications. It is a direct competitor to Neuronetics in the TMS device market and shapes the competitive landscape for any clinic building a TMS offering.
- Magstim: Magstim is a long-established manufacturer of TMS stimulators and supplies research and clinical-grade systems globally. Its presence in the device market influences technology choice and pricing for any TMS clinic operator.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat2 records
Key risks6 records
Key highlights6 records
Customer concentration
Achieve TMS social profiles
Digital presenceAchieve TMS compliance and trust
Trust signalCompliance2 records
Achieve TMS financial estimates
Financial estimateRevenue estimate
Valuation estimate
Achieve TMS leadership team
Management profileNumber of profiles
Achieve TMS funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Achieve TMS M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Achieve TMS
What does Achieve TMS do?
Achieve TMS provides in-person depression treatment services at physical clinic locations, delivering FDA-cleared NeuroStar TMS (Transcranial Magnetic Stimulation) therapy and FDA-approved SPRAVATO (esketamine) nasal spray treatments to adults suffering from depression, including treatment-resistant depression and major depressive disorder with suicidal thoughts. Treatments are administered by clinical staff and billed primarily through major insurance carriers, with Medicare and Medicaid coverage available at various locations and the company handling all insurance paperwork, claims, and appeals on the patient's behalf.
Is Achieve TMS a public or private company?
Achieve TMS is a private company. It is classified as unknown and is currently operating.
When was Achieve TMS founded?
Achieve TMS was founded in 2016.
Where is Achieve TMS based?
Achieve TMS is headquartered in San Diego, United States, in the North America region.
How does Achieve TMS make money?
One revenue line is on record: patient Treatment Services.
Who are Achieve TMS's main competitors?
Emerging players on record are Cerebral, Talkspace and Brightside Health. Direct peers are Mindpath Health and Greenbrook TMS NeuroHealth Centers. Broad incumbents are LifeStance Health, Acadia Healthcare, Neuronetics, Brainsway and Magstim.
Does Achieve TMS have an API?
No public API is recorded for Achieve TMS.